Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

39.21 -0.82 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
20 21 Next >
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in game-changing businesses. 
Via The Motley Fool
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
From Farallon Capital Management L.L.C.
Via Business Wire
8 Analysts Have This to Say About Exelixis
 
Via Benzinga
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Exelixis: Q1 Earnings Insights
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Exelixis
 
Via Benzinga
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These companies can take investors on a lucrative ride, and all for the price of a few lattes. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip
A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals. 
Via The Motley Fool
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns
Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board,  
Via Benzinga
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
From Farallon Capital Management L.L.C.
Via Business Wire
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
From Farallon Capital Management L.L.C.
Via Business Wire
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Exelixis, Inc.
Via Business Wire
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These cheap stocks have the potential to skyrocket over the long haul. 
Via The Motley Fool
Nasdaq Bear Market: 5 Sensational Growth Stocks You'll Regret Not Buying on the Dip
Opportunistic investors would be wise to pounce on innovative growth stocks following a 33% decline in the Nasdaq Composite. 
Via The Motley Fool
Exelixis Advances Board Refreshment Plan
From Exelixis, Inc.
Via Business Wire
Exelixis Reiterates Commitment to Shareholder Value Creation
From Exelixis, Inc.
Via Business Wire
2 Under-the-Radar Biotech Stocks to Buy in 2023
Both companies have game-changing product portfolios that should result in stock price growth. 
Via The Motley Fool
Facebook Turns To Generative AI For Help, FedEx Consolidates, UBS Executives Say Surprise Credit Suisse Deal 'Major Challenge:' Today's Top Stories
Benzinga 
Via Benzinga
Farallon Capital Might Undertake Proxy Fight Against Exelixis, Nominates Three Directors
 
Via Benzinga
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
From Farallon Capital Management L.L.C.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback